Survey of oncologists about shortages of cancer drugs

New England Journal of Medicine

Volumn 369, Issue 25, 2013, Pages 2463-2464

  Gogineni, Keerthi ^a   Shuman, Katherine L ^b   Emanuel, Ezekiel J ^b  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CAPECITABINE; CYTARABINE; DOXORUBICIN; FLUOROURACIL; FOLINIC ACID; GENERIC DRUG;

BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RECURRENCE; COLON CANCER; DISEASE ACTIVITY; DRUG COST; DRUG INFORMATION; HEALTH SURVEY; HUMAN; LETTER; LEUKEMIA; LYMPHOMA; MALIGNANT NEOPLASTIC DISEASE; MEDICAL DECISION MAKING; METASTASIS POTENTIAL; NOMENCLATURE; ONCOLOGIST; PRESCRIPTION; PRIORITY JOURNAL; PUBLIC HEALTH PROBLEM; RETROSPECTIVE STUDY; UNITED STATES;

EID: 84890377713     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1307379     Document Type: Letter

References (5)

1. U.S. Food and Drug Administration. Editor's choice: StatBite drug shortages, 2001-2010. J Natl Cancer Inst 2011;103:915.
2. Metzger ML, Billett A, Link MP. The impact of drug shortages on children with cancer - the example of mechlorethamine. N Engl J Med 2012;367:2461-3.
3. Economic analysis of the causes of drug shortages. ASPE Issue Brief. Washington, DC: Office of Science and Data Policy-Department of Health and Human Services, October 2011.
4. André T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004;350:2343-51.
5. Mariotto AB, Yabroff KR, Shao Y, Feuer EJ, Brown ML. Projections of the cost of cancer care in the United States: 2010-2020. J Natl Cancer Inst 2011;103:117-28. [Erratum, J Natl Cancer Inst 2011;103:699.]